Human Papillomavirus Protein E7 (E7) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Human Papillomavirus Protein E7 (E7) – Pipeline Review, H2 2016’, provides in depth analysis on Human Papillomavirus Protein E7 (E7) targeted pipeline therapeutics.

The report provides comprehensive information on the Human Papillomavirus Protein E7 (E7) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Human Papillomavirus Protein E7 (E7) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Human Papillomavirus Protein E7 (E7)

The report reviews Human Papillomavirus Protein E7 (E7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Human Papillomavirus Protein E7 (E7) targeted therapeutics and enlists all their major and minor projects

The report assesses Human Papillomavirus Protein E7 (E7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Human Papillomavirus Protein E7 (E7) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Human Papillomavirus Protein E7 (E7)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Human Papillomavirus Protein E7 (E7) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Abion Inc

Advaxis Inc

Bioleaders Corporation

BioNTech AG

Cancer Research Technology Ltd

Etubics Corp

Formune SL

Genexine Inc

Genticel S.A.

iBio Inc

Immunovaccine Inc

Inovio Pharmaceuticals Inc

Kite Pharma Inc

MedImmune LLC

Selecta Biosciences Inc

Tomegavax Inc

Transgene SA

VLPbio

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Human Papillomavirus Protein E7 (E7) Overview 9

Therapeutics Development 10

Human Papillomavirus Protein E7 (E7) - Products under Development by Stage of Development 10

Human Papillomavirus Protein E7 (E7) - Products under Development by Therapy Area 11

Human Papillomavirus Protein E7 (E7) - Products under Development by Indication 12

Human Papillomavirus Protein E7 (E7) - Pipeline Products Glance 13

Late Stage Products 13

Early Stage Products 14

Unknown Stage Products 15

Human Papillomavirus Protein E7 (E7) - Products under Development by Companies 16

Human Papillomavirus Protein E7 (E7) - Products under Development by Universities/Institutes 20

Human Papillomavirus Protein E7 (E7) - Therapeutics Assessment 22

Assessment by Monotherapy/Combination Products 22

Assessment by Mechanism of Action 23

Assessment by Route of Administration 24

Assessment by Molecule Type 26

Human Papillomavirus Protein E7 (E7) - Companies Involved in Therapeutics Development 28

Abion Inc 28

Advaxis Inc 29

Bioleaders Corporation 30

BioNTech AG 31

Cancer Research Technology Ltd 32

Etubics Corp 33

Formune SL 34

Genexine Inc 35

Genticel S.A. 36

iBio Inc 37

Immunovaccine Inc 38

Inovio Pharmaceuticals Inc 39

Kite Pharma Inc 40

MedImmune LLC 41

Selecta Biosciences Inc 42

Tomegavax Inc 43

Transgene SA 44

VLPbio 45

Human Papillomavirus Protein E7 (E7) - Drug Profiles 46

ABN-301 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

Antibodies to Inhibit E7 for HPV Associated Cancer - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

Aptamer to Target HPV E7 Protein for Cervical Cancer - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

axalimogene filolisbac - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

BLSILSB-710c - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

Cellular Immunotherapy to Target HPV-16 E7 Protein for Head and Neck Cancer and Cervical Cancer - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

CerviVax - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

DPXE-7 - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

EDA-HPVE7 - Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

Enzymes to Inhibit HPV E7 for Human Papillomavirus Related Cervical Cancer - Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

ETBX-041 - Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

GLBL-101c - Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

GTL-001 - Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

GTL-002 - Drug Profile 79

Product Description 79

Mechanism Of Action 79

R&D Progress 79

GX-188E - Drug Profile 80

Product Description 80

Mechanism Of Action 80

R&D Progress 80

human papillomavirus [Serotype 16] vaccine - Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

human papillomavirus [serotype 16] vaccine 2 - Drug Profile 83

Product Description 83

Mechanism Of Action 83

R&D Progress 83

human papillomavirus [serotypes 16] vaccine - Drug Profile 84

Product Description 84

Mechanism Of Action 84

R&D Progress 84

human papillomavirus vaccine - Drug Profile 85

Product Description 85

Mechanism Of Action 85

R&D Progress 85

INO-3106 - Drug Profile 86

Product Description 86

Mechanism Of Action 86

R&D Progress 86

INO-3112 - Drug Profile 87

Product Description 87

Mechanism Of Action 87

R&D Progress 87

PVX-01 - Drug Profile 90

Product Description 90

Mechanism Of Action 90

R&D Progress 90

SEL-701 - Drug Profile 91

Product Description 91

Mechanism Of Action 91

R&D Progress 91

TA-CIN - Drug Profile 92

Product Description 92

Mechanism Of Action 92

R&D Progress 92

TG-4001 - Drug Profile 93

Product Description 93

Mechanism Of Action 93

R&D Progress 93

Vaccine for HPV Associated Cervical Cancer - Drug Profile 95

Product Description 95

Mechanism Of Action 95

R&D Progress 95

Vaccine to Target HPV E7 Protein for Cervical Cancer - Drug Profile 96

Product Description 96

Mechanism Of Action 96

R&D Progress 96

Vaccine to Target IL-2 and E7 Protein for Cervical Cancer and Oropharyngeal Cancer - Drug Profile 97

Product Description 97

Mechanism Of Action 97

R&D Progress 97

VGX-3100 - Drug Profile 98

Product Description 98

Mechanism Of Action 98

R&D Progress 98

Vvax-001 - Drug Profile 101

Product Description 101

Mechanism Of Action 101

R&D Progress 101

Human Papillomavirus Protein E7 (E7) - Dormant Projects 102

Human Papillomavirus Protein E7 (E7) - Discontinued Products 104

Human Papillomavirus Protein E7 (E7) - Featured News & Press Releases 105

Nov 14, 2016: Inovios Cancer Immunotherapy (INO-3112) Generates T Cell Immune Responses in Tumor Tissue and Peripheral Blood in Patients with HPV-Associated Head and Neck Cancer 105

Nov 11, 2016: Advaxis to Present Phase 1 Combination Data and New Preclinical Data Using AXAL at Upcoming Society for Immunotherapy of Cancer (SITC) 2016 Annual Meeting 106

Oct 24, 2016: Inovio Announces FDA Request for Additional Information For Phase III Program; Trial Initiation Delayed 107

Oct 24, 2016: Advaxis Announces GOG-0265 12-month Overall Survival Rate of

37.5% in Stage 2 107

Oct 20, 2016: Advaxis Initiates Phase 3 Study of Axalimogene Filolisbac 108

Oct 12, 2016: Inovio Expands Executive Team to Advance its DNA Immunotherapy Product Portfolio 109

Oct 11, 2016: Advaxis Research Reception at SITC 2016 to Review Recent AXAL Highlights and the AXAL-Durvalumab Combination Poster 110

Sep 26, 2016: Advaxis’ Lm Technology Immunotherapies to be Showcased in Three Poster Presentations at SITC Annual Meeting 110

Aug 11, 2016: Advaxis Announces that Phase 2 Head and Neck Cancer Study with AXAL Advances to Second Stage 110

Jul 26, 2016: Phase 1/2 Combination Trial of AXAL and Durvalumab Completes Second Dose-Escalation Cohort 111

Jul 21, 2016: Advaxis AXAL Receives Fast Track Designation by the FDA as Adjuvant Therapy for High-Risk Locally Advanced Cervical Cancer Patients 111

Jul 18, 2016: European Medicines Agency Committee Classifies Advaxis’ Axalimogene Filolisbac as an Advanced-Therapy Medicinal Product 112

Jul 06, 2016: FDA Grants Special Protocol Assessment to Advaxis Phase 3 Study of AXAL in Patients with Cervical Cancer 113

Jul 06, 2016: Genticel Appoints Eumedix as Strategic Advisor to Support Company’S Access to Innovative Drug Candidates 114

Jun 23, 2016: Genticel Reports 18 Month Interim Analysis of GTL001 Phase 2 Trial in HPV16/18 Infected Women 114

Appendix 115

Methodology 115

Coverage 115

Secondary Research 115

Primary Research 115

Expert Panel Validation 115

Contact Us 115

Disclaimer 116

List of Tables

List of Tables

Number of Products under Development for, H2 2016 10

Number of Products under Development by Therapy Area, H2 2016 11

Number of Products under Development by Indication, H2 2016 12

Comparative Analysis by Late Stage Development, H2 2016 13

Comparative Analysis by Early Stage Products, H2 2016 14

Comparative Analysis by Unknown Stage Development, H2 2016 15

Number of Products under Development by Companies, H2 2016 16

Products under Development by Companies, H2 2016 17

Products under Development by Companies, H2 2016 (Contd..1) 18

Products under Development by Companies, H2 2016 (Contd..2) 19

Number of Products under Investigation by Universities/Institutes, H2 2016 20

Products under Investigation by Universities/Institutes, H2 2016 21

Assessment by Monotherapy/Combination Products, H2 2016 22

Number of Products by Stage and Mechanism of Action, H2 2016 23

Number of Products by Stage and Route of Administration, H2 2016 25

Number of Products by Stage and Molecule Type, H2 2016 27

Pipeline by Abion Inc, H2 2016 28

Pipeline by Advaxis Inc, H2 2016 29

Pipeline by Bioleaders Corporation, H2 2016 30

Pipeline by BioNTech AG, H2 2016 31

Pipeline by Cancer Research Technology Ltd, H2 2016 32

Pipeline by Etubics Corp, H2 2016 33

Pipeline by Formune SL, H2 2016 34

Pipeline by Genexine Inc, H2 2016 35

Pipeline by Genticel S.A., H2 2016 36

Pipeline by iBio Inc, H2 2016 37

Pipeline by Immunovaccine Inc, H2 2016 38

Pipeline by Inovio Pharmaceuticals Inc, H2 2016 39

Pipeline by Kite Pharma Inc, H2 2016 40

Pipeline by MedImmune LLC, H2 2016 41

Pipeline by Selecta Biosciences Inc, H2 2016 42

Pipeline by Tomegavax Inc, H2 2016 43

Pipeline by Transgene SA, H2 2016 44

Pipeline by VLPbio, H2 2016 45

Dormant Projects, H2 2016 102

Dormant Projects (Contd..1), H2 2016 103

Discontinued Products, H2 2016 104

List of Figures

List of Figures

Number of Products under Development for, H2 2016 10

Number of Products under Development by Therapy Area, H2 2016 11

Number of Products under Development by Top 10 Indication, H2 2016 12

Comparative Analysis by Late Stage Development, H2 2016 13

Comparative Analysis by Early Stage Products, H2 2016 14

Assessment by Monotherapy/Combination Products, H2 2016 22

Number of Products by Stage and Mechanism of Actions, H2 2016 23

Number of Products by Routes of Administration, H2 2016 24

Number of Products by Stage and Routes of Administration, H2 2016 24

Number of Products by Molecule Types, H2 2016 26

Number of Products by Stage and Molecule Type, H2 2016 26

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports